Salt Lake City-based Myriad Genetics, Inc. announced that its BRACAnalysis CDx® test accurately identifies patients with ovarian cancer for a second-line treatment with olaparib. The announcement came as a result of a...more
11/18/2016
/ Biotechnology ,
BRCA ,
Cancer ,
Clinical Trials ,
Diagnostic Tests ,
FDA Approval ,
Human Genes ,
Life Sciences ,
Medical Devices ,
Myriad ,
Pharmaceutical Industry
GlaxoSmithKline (GSK) announced that it is partnering with Verily Life Sciences LLC to form Galvani Bioelectronics. According to the press release, GSK and Verily will contribute IP rights and an investment of $712.7 million...more